|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.53 CNY | +2.41% |
|
+5.33% | +8.01% |
| Apr. 19 | KPC Pharmaceuticals,Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 17 | Kunyao Group Receives Clinical Trial Approval for FMF Drug | MT |
KPC Pharmaceuticals, Inc. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 6,192.72 million compared to CNY 6,027.71 million a year ago. Net income was CNY 372.68 million compared to CNY 433.86 million a year ago.
Basic earnings per share from continuing operations was CNY 0.4915 compared to CNY 0.5722 a year ago. Diluted earnings per share from continuing operations was CNY 0.4915 compared to CNY 0.5722 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.01% | 2.35B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
KPC PHARMACEUTICALS,INC 
